The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint

Chui Chui Ho1, Wai Yi Siu, Jeremy P H Chow

  • 1Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.

Experimental Cell Research
|February 15, 2005
PubMed

Insights

Adriamycin (ADR) chemotherapy relies on DNA damage checkpoints. This study reveals CHK1, not CHK2, is crucial for ADR-induced cell cycle arrest, impacting cancer treatment strategies.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • Cancer Therapeutics

Background:

  • Topoisomerase II inhibitors like Adriamycin (ADR) are vital chemotherapeutics.
  • ADR triggers DNA damage checkpoints involving ATM, ATR, CHK1, and CHK2.
  • The specific roles of CHK1 and CHK2 in ADR-induced checkpoints require clarification.

Purpose of the Study:

  • To determine whether CHK1 or CHK2 is essential for Adriamycin-induced cell cycle arrest.
  • To investigate the functional consequences of disrupting CHK1 or CHK2 in response to ADR.
  • To explore the potential implications of CHK1 expression in hepatocellular carcinoma (HCC).

Main Methods:

  • Utilizing dominant-negative mutants, short hairpin RNA (shRNA), and knockout cell lines.
  • Assessing phosphorylation of CHK1 and CHK2 following Adriamycin treatment.
  • Analyzing cell cycle progression markers such as CDC25A and CDC2, and histone H3 phosphorylation.

Main Results:

  • Both CHK1 and CHK2 were phosphorylated upon Adriamycin exposure.
  • CHK1, but not CHK2, was found to be critical for Adriamycin-induced cell cycle arrest.
  • Disrupting CHK1 function led to checkpoint bypass, increased CDC25A and CDC2 activity, elevated histone H3 phosphorylation, and reduced cell survival.
  • CHK1 was upregulated as an inactive form in primary hepatocellular carcinoma (HCC).

Conclusions:

  • CHK1 plays a pivotal role in the cell cycle checkpoint response to Adriamycin.
  • CHK2 is dispensable for Adriamycin-induced cellular responses.
  • The presence of inactive CHK1 in HCC suggests potential therapeutic strategies involving topoisomerase II inhibitors.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...